Sazzad Hossain

• Defined the InMed Pharmaceuticals Inc’s strategic R&D roadmap by providing exemplary scientific input into company’s research and development programs in order to support the overall corporate strategy & de facto operational leadership in identifying, evaluating and developing novel preclinical drug development opportunities and candidates and progressing them into IND-enabling studies and into human PoC clinical trials. • Maintaining the highest quality of scientific foundations of the company’s drug discovery & development process utilizing proprietary “Intelligent Drug Development Platform (IDP)” to increase drug development pipeline and providing strategic input for company’s mid- and long-term goals from the scientific standpoint. • Proving other members of Senior Staff with continuous scientific input in the areas of business development, clinical development and commercialization, financial planning and execution, regulatory matters, manufacturing, extramural funding processes and initiatives. • Responsible for the composition, relationship development, and value adding output from company’s Scientific Advisory Board. Attracting, hiring and developing high performing managers and scientists, leading a team of 26 scientists (14 PhD and 12 M.Sc). • Established partnerships with academic institutions, with other pharmaceutical companies, CRO’s and Health Authorities, managing the company’s patent estate. • Expert scientific knowledge in the area of physiology, pharmacology and experimental therapy, strong publication record in peer reviewed journals across therapeutic areas and patent record, excellent understanding of drug target validation and the exploratory drug development process. Providing scientific and business development input for licensing contracts.

Entourage Biosciences Inc is developing innovative healthcare products targeting our body's endocannabinoid system by exploring the entourage effects of phytotherapeutic compounds found in nature.

Drug Discovery Leader over 15 years of biotech/pharmaceutical experience with small molecule & biologics in multiple disease indications. Accelerated drug discovery and commercialization process with combined experience in preclinical in vivo Pharmacology, DMPK, Safety &Toxicology. Strategic design of new Natural Health Product Development: design, execution and interpretation of efficacy, safety and toxicology studies, and regulatory support for registration of new & existing products. Generated hundreds of millions of dollars in revenue by leading development of multiple successful compounds. Specialties: ● Early stage non-clinical safety & toxicology ● GLP & Non-GLP Safety & Toxicological Studies. ● In vivo pharmacology & Animal Model Development ● Natural Health Product Development ● Regulatory submissions ● CRO study design & management ● Project management. ● Statistical Analysis (SAS, SPSS, WinNonlin) Hired to launch first-ever drug evaluation programs for BRI, including ADME, in vivo pharmacology, toxicology, and DMPK capabilities. Hired and trained technical personnel, planed and purchased equipment needs for state-of-the-art $2.5M laboratory, and validated a variety of animal models. Pharmacological and in vivo projects target chronic conditions, especially cancer and cardiovascular and ocular diseases. Supervised 2 PhDs, 6 technicians, and 4 support staffs. ● Advanced in-house research & drug development and conducted contract research for Canadian and Multinational pharma companies - preclinical efficacy, non-GLP safety & toxicology, PK/PD studies to accelerate drug discovery process. ● Designed and managed GLP toxicology studies conducted at CRO's ● Conducted various industrial collaborative research projects with Canadian SME’s and generated revenue totalling $0.5 M in 2012 ● Developed various research projects & grant proposals independently or in teams for Canadian Funding Agencies.

Recruited from University of British Columbia and away from assistant professorship offer at a U.S. university by Professor Michael Hayden. Earned rapid promotion from Senior Scientist to Associate Director while simultaneously serving as principal scientist in development of mission-critical compounds. ● Successfully completed due diligence meeting with Pharmaceutical companies: Novartis Pharma AG, Takeda Pharmaceuticals, and Roche resulting licensing agreements & increased portfolio value ~$500M. ● Prepared FDA’s IND enabling documents and Investigator’s brochure (IB) for new drug candidates. ● Developed topical drug development program for XEN402 licensed to Teva Pharmaceuticals (~$335M) and recently FDA granted XEN402 as Orphan Drug for the treatment of pain associated with Erythromelalgia.

● Provided scientific & technical leadership & managed group of scientists & technical personals. ● Managed the following drug discovery & development projects: Oral XEN402(Pain- Phase 3), Topical XEN402(Pain - Phase 2), XEN403- Oral (Pain Phase 1 Trial). ● Collaborated with medicinal chemistry group to optimize lead compounds. ● Conducted efficacy, PK/PD, non-GLP safety & toxicological studies . ● Designed & managed GLP toxicological studies conducted at CRO's ● Increased portfolio value ~$232M by managing licensing of Stearoyl-CoA Desaturase-1 (SCD1) lead compound to Novartis Pharma AG .

Research Associate - CMMT/UBC. Dept. of Medical Genetics (2000-2003) ● Established & managed CFI-funded “Transgenic Mouse Behaviour Phenotyping” laboratory at Centre for Molecular Medicine & Therapies of UBC. ● Trained graduate students and post-doctoral researchers on behavioural phenotype of transgenic and knockout mice. Research Associate, Dept. of Food Nutrition & Agricultural Sciences (1996–2000) ● Received BC Research Council Industrial Awards to study the “Food and Pharmaceutical application of chitin produced from shrimp waste of Fraser River Fish Industries" sponsored by BC SME; conducted studies & provided technical solutions to increase application of chitin in pharmaceutical and animal feed formulations. ● Conducted research to reduce the ground water nitrogen and phosphorus contamination from intensive livestock production in Fraser Valley to reduce the environmental impact.

Conducted research and taught pharmacology, physiology & nutrition . Performed outreach and technology transfer to Industry. Built and managed new lab. ● Setup laboratory & Brought micro-mineral and vitamin research techniques to Brazil for the first time. ● Supervised 9 MSc and 3 PhD students – 3 of them are now faculty members in Brazilian universities. ● Published 24 peer-reviewed research papers.